Hemochromatosis: a risk factor for breast cancer?

Do pathogenic HFE variants (C282Y, H63D) increase breast cancer risk? A review and meta-analysis with a proposal for personalized surveillance.

Hereditary hemochromatosis and breast cancer are two major public health problems. HFE gene variants, C282Y and H63D, responsible for most cases of hemochromatosis, may contribute to carcinogenesis through iron overload, oxidative stress, and hormonal modulation. This study aimed to assess the association between HFE variants and breast cancer risk and to propose a personalized monitoring strategy.

Developed based on: Buttignol, M., Bouche, C., Chrétien, M., Taris, N., Ozmen, T., & Mathelin, C. (2025). Hemochromatosis: A Risk Factor for Breast Cancer? Systematic Review and Meta-Analysis. European Journal of Breast Health. Advance online publication. https://doi.org/10.4274/ejbh.galenos.2025.2025-7-1 : journal page (accessed: 11.09.2025).

Key points

  • Hereditary hemochromatosis is a common genetic disorder in people of European ancestry, and its main pathogenic variants, C282Y and H63D, may contribute to carcinogenesis via iron overload and oxidative stress.
  • The meta-analysis included eight studies and over 53,000 participants to assess the association between HFE mutations and breast cancer risk.
  • Although the pooled analysis did not show a statistically significant association, there was a consistent trend toward increased breast cancer risk, particularly in C282Y homozygotes.
  • Heterogeneity across studies was not explained by genotype, zygosity, year of publication, or methodological quality, but sensitivity analyses supported the robustness of the signal.
  • Intensified screening protocols are proposed for carriers of pathogenic HFE variants, in particular C282Y homozygotes. Pending further data, screening might include more frequent clinical and imaging evaluations, potentially with adjunct modalities such as breast ultrasound or MRI.

Breast cancer and hereditary hemochromatosis

Breast cancer and hereditary hemochromatosis are relatively common conditions, especially among people of European descent. Emerging evidence suggests a potential link between them, with iron overload considered a possible factor contributing to breast carcinogenesis. Breast cancer is the most common cancer in women, with an estimated 2,296,840 new cases worldwide in 2022. It also remains a leading cause of cancer death in women, accounting for about 666,103 deaths annually. Incidence and mortality are steadily rising, and by 2040 more than 3 million new cases and over 1 million deaths are expected. Hereditary hemochromatosis is one of the most common genetic diseases in Northern European populations, with an estimated homozygous prevalence of 1/200 to 1/400.

Hereditary hemochromatosis is an autosomal recessive genetic disorder caused by excessive iron absorption, resulting in toxic iron accumulation in organs, particularly the liver, heart, pancreas, and joints. The most common form is associated with biallelic pathogenic variants of the HFE gene on chromosome 6, especially C282Y and H63D (type 1), particularly in Northern Europeans, among whom about 1 in 200 are C282Y homozygotes and 1 in 10 are C282Y heterozygotes. Other genes are implicated to a lesser extent, such as HJV or HAMP (type 2) in juvenile forms, TfR2 (type 3) and FPN (type 4). A common feature of these pathogenic variants is disruption of the signaling system responsible for hepcidin synthesis, leading to increased intestinal iron absorption. Excess iron accumulates in tissues as ferritin, driving progressive toxicity, especially in key organs.

Iron is essential, but in excess it is carcinogenic. Excess, particularly readily absorbed heme iron from red meat, promotes oxidative stress, iron-driven DNA damage, and higher serum ferritin levels, which are linked to increased cancer risk. In breast tissue, iron acts synergistically with estrogen metabolites to generate reactive species, a process that intensifies after menopause as iron stores rise. Hemochromatosis often coexists with diabetes and obesity, additional breast cancer risk factors. Although hemochromatosis clearly increases liver cancer risk and risk for other malignancies, scientific data on breast cancer have been inconsistent. This review and meta-analysis aimed to clarify the relationship between hemochromatosis and breast cancer and to propose personalized surveillance for affected women.

Materials and methods

This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (prismastatement.org).

Eligible publications were searched in PubMed, published between 2000 and 2025, using the terms “hemochromatosis”, “pathogenic HFE variants”, and “breast cancer”.

We included studies assessing the association between pathogenic HFE variants and cancer risk; study designs included prospective and retrospective cohort studies, case-control studies, meta-analyses, and systematic reviews.

We excluded case series, case reports, and abstracts; studies lacking sufficient data; and animal studies.

Only articles published in English and French were considered.

Summary of findings

1. Studies showing no significant association between hemochromatosis and breast cancer risk

A multicenter retrospective cohort study conducted between 1997 and 2017 in eight university hospitals in Sweden included 3,645 individuals carrying homozygous or compound heterozygous pathogenic HFE variants, matched by age, sex, and country of residence with 36,423 population controls. The study found no significant differences in breast cancer risk compared to controls.

Similarly, a prospective European study of 451,143 UK Biobank participants aged 40–70 years, with a mean follow-up of 11.6 years, assessed the risk of non-liver cancers in carriers of pathogenic HFE variants. It reported an increased prostate cancer risk in C282Y homozygous men but no increased risk of other cancers, including breast cancer in women, for either C282Y or H63D.

A Brazilian case-control study comparing 68 women with operable breast cancer (mean age 54.2 years) to 85 control women without a family history of cancer and not using hormone therapy also found no association between H63D and C282Y variants and breast cancer risk.

A German study of 688 white women under 80 years of age diagnosed with breast cancer within the preceding 6 months analyzed 19 polymorphisms in iron-metabolism genes, including HFE. It found no significant differences in allele or genotype frequencies between breast cancer cases and controls, suggesting these variants do not directly affect breast cancer incidence. However, a possible association was observed between the HFE C282Y allele and higher lymph node involvement, potentially related to tumor progression, though limited by small sample size.

2. Studies showing a significant association between hemochromatosis and breast cancer risk

In contrast, Kallianpur et al. reported a strong association between pathogenic HFE C282Y variants and increased breast cancer risk, with important public health implications for genetic testing and prevention. They compared the frequency of the C282Y pathogenic variant across 168 patients who underwent chemotherapy or hematopoietic cell transplantation for cancer at Vanderbilt University Medical Center (1995–1998). Women with breast cancer were compared with women treated for non-breast cancers, including hematologic malignancies, as well as a cancer-free clinic cohort and national population data. The frequency of at least one C282Y allele among breast cancer cases was higher than in the clinic cohort, the general population, and other carefully matched non-breast cancer cases. Breast cancer risk increased with the number of C282Y alleles, and serum iron levels were higher in breast cancer patients carrying these variants.

A prospective cohort using the Melbourne Collaborative Cohort Study followed 28,509 participants aged 27–75 years, recruited between 1990 and 1994, for a mean of 14 years to examine cancer risk in HFE C282Y carriers, particularly breast, colorectal, and prostate cancer. It found a significant 2.39-fold increase in breast cancer risk among C282Y homozygotes, whereas compound heterozygotes C282Y/H63D showed no increase.

A 2016 meta-analysis including 36 studies with 87,028 participants (13,680 cancer cases and 73,348 controls) also found a trend toward approximately twofold higher breast cancer risk in patients homozygous for HFE C282Y. However, no increased risk was found for H63D carriers, in contrast to Gunel-Ozcan et al., who reported a significant association for H63D in Turkish women with breast cancer versus controls.

Another case-control study in Russian women with hormone-dependent cancers (breast, ovarian, endometrial) reported a significant increase in breast cancer risk in women older than 57 years carrying heterozygous or homozygous H63D. No such association was found for C282Y.

Zhang et al. performed a meta-analysis including 20 studies (1999–2005): seven on breast cancer risk in HFE C282Y carriers (total 2,353 cases and 19,171 controls) and five on H63D (1,570 cases and 2,449 controls). An association was observed only for C282Y homozygotes, suggesting increased breast cancer risk in this subgroup. No association was found for H63D.

This meta-analysis

We conducted a meta-analysis to examine the association between pathogenic hereditary hemochromatosis variants (mainly C282Y and H63D) and breast cancer risk, including eight studies totaling 73,981 patients. Two recent large studies from 2021 and 2022 were added beyond those included in Lv et al. and Zhang et al., improving statistical power.

Discussion and conclusions

The international literature shows conflicting results regarding the link between hemochromatosis and breast cancer. Some studies, such as Hagström et al. and UK Biobank, did not find a significant increase in breast cancer risk in women homozygous for HFE C282Y. Others, such as Kallianpur et al. and Osborne et al., indicated a significant association between these variants and increased breast cancer risk. Several methodological and biological factors may explain the discrepancies. Study design, sample size, and follow-up duration matter: smaller cohorts (e.g., Kallianpur et al.) may capture high-risk subpopulations, whereas large cohorts (e.g., UK Biobank) offer power but may dilute effects in specific groups (e.g., postmenopausal women).

Clinical penetrance of HFE-related hereditary hemochromatosis, especially C282Y homozygosity, is variable and crucial for cancer-risk monitoring. Although only 10–33% of people with this genotype develop clinically overt hemochromatosis, a much larger proportion shows elevated biochemical iron markers, including higher ferritin and transferrin saturation. This gap between biochemical and clinical expression argues for individualized monitoring rather than relying solely on genotype. Compound heterozygotes and H63D homozygotes typically have mild iron marker elevations and generally do not develop progressive iron-related organ damage unless additional risk factors are present.

Mechanistic links between iron excess and breast carcinogenesis are complex and incompletely understood. Iron-induced oxidative stress, DNA damage, and genomic instability support a carcinogenic role. Interactions between iron and estrogens, as suggested by Marques et al. and Wyllie & Liehr, may explain stronger risk signals post-menopause, when iron stores rise and hormonal milieu shifts. Conflicting findings for H63D’s role persist: while Lv et al. found no association, Gunel-Ozcan et al. suggested increased risk with H63D. These differences underscore the need for further, better-controlled studies including modifiers such as menopausal status, environmental factors, and metabolic comorbidities.

Monitoring iron status in HFE variant carriers is especially relevant in oncology, as emerging evidence links iron excess with tumor progression. Higher blood iron and transferrin saturation are associated with increased risk of distant metastases in breast cancer, likely via enhanced oxidative stress, immune evasion, and pro-metastatic niche formation. In a retrospective, single-center study at University Hospitals Leuven, De Troy et al. examined iron metabolism markers at the time of early breast cancer diagnosis and risk of distant metastasis. Among 1,113 women with unilateral, unifocal breast cancer and available iron profiles (serum iron, ferritin, and transferrin saturation) within six weeks of diagnosis, 10% developed secondary metastases over a median follow-up of seven years. Multivariable Cox regression showed that each 10% increase in transferrin saturation corresponded to a 19% increase in metastasis risk, and each 10 µg/dL increase in serum iron corresponded to a 6% increase. Ferritin was not significantly associated with metastasis occurrence. These findings suggest that elevated blood iron and saturation at diagnosis may help create a microenvironment conducive to metastasis and support targeted iron-metabolism approaches (e.g., chelation or inducing ferroptosis) as potential therapeutic strategies in breast cancer.

In this context, iron overload may act not only as a metabolic comorbidity but also as a modifier of tumor behavior. Environmental and physiological factors — age, sex, alcohol intake, metabolic syndrome, viral hepatitis, menopausal status — strongly influence iron-overload progression and may synergize with cancer-related pathways. Secondary genetic modifiers (e.g., HAMP, HJV, BMP variants), high dietary heme-iron intake, or long-term acid-suppressive therapy can further modulate iron burden and treatment needs.

Although several studies evaluated the association between HFE variants and breast cancer risk, none specifically described histologic subtypes of breast cancer in women with hereditary hemochromatosis. The literature focuses on genetic links, iron metabolism, and overall incidence, with little detail on tumor morphology or receptor status. While some studies suggest increased breast cancer incidence among HFE variant carriers (H63D or C282Y), data on age at diagnosis remain limited. Notably, one study in a Russian population found that H63D-related risk increased significantly in women older than 57 years.

This meta-analysis offers several advantages over prior work: (1) all included studies are relatively recent (last 20 years); (2) geographic and ethnic diversity (Europe — Germany, Sweden, UK, Russia, Turkey; North and South America — USA, Brazil; Australia) supports generalizability across genetic backgrounds and environments; (3) stratified analyses by specific HFE genotypes (C282Y homozygotes, H63D carriers, compound heterozygotes) enable more granular, genotype-specific breast cancer risk assessment in women; (4) inclusion of large prospective cohorts (UK Biobank, Melbourne Cohort) provides high-quality population evidence with long follow-up; and (5) age- and sex-adjusted data allow exploration of effect modifiers such as menopausal status.

Overall, we observed a potential association between HFE C282Y and H63D pathogenic variants and increased breast cancer risk. Although the trend did not reach statistical significance, the consistent signal justifies further large-scale, lower-heterogeneity studies to better quantify this relationship and potentially support tailored breast surveillance in carriers. Indeed, the UK Age Trial — a randomized study of 160,921 women — showed that annual mammography at ages 40–48 reduced breast-cancer mortality by 25% in the first 10 years, preventing one death per 1,000 screened women, without long-term overdiagnosis or other mortality increases.

Hereditary hemochromatosis and breast cancer are two major public health issues. Although this meta-analysis did not demonstrate a statistically significant association between pathogenic HFE variants, especially C282Y and H63D, and breast cancer risk, we observed a consistent tendency toward increased risk, particularly among C282Y homozygotes.

Given the absence of randomized trials with mortality endpoints, the findings do not justify clinical practice changes at this stage. They do, however, motivate prospective studies to evaluate whether women carrying these pathogenic variants — especially C282Y/C282Y homozygotes — could benefit from tailored breast-cancer surveillance strategies. Such research could determine whether personalized screening — potentially including more frequent assessments or advanced imaging — improves early detection in this genetically predisposed population.

References

Hemochromatosis: A Risk Factor for Breast Cancer? Systematic Review and Meta-Analysis.
European Journal of Breast Health, 2025 — Advance online publication.
Full text

Did you find it useful?

This portal is for informational and educational purposes only. It does not constitute medical advice and cannot replace consultation with a qualified physician.

All articles